Cargando…
Successful Desensitization of a Patient with Rituximab Hypersensitivity
Rituximab is a monoclonal antibody which targets CD20 in B cells that is used for the treatment of CD20 positive oncologic and hematologic malignancies. Rituximab causes hypersensitivity reactions during infusions. The delay of treatment or loss of a highly efficient drug can be prevented by rapid d...
Autores principales: | Ataca, Pinar, Atilla, Erden, Kendir, Resat, Bavbek, Sevim, Ozcan, Muhit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320878/ https://www.ncbi.nlm.nih.gov/pubmed/25685566 http://dx.doi.org/10.1155/2015/524507 |
Ejemplares similares
-
Successful Bosutinib Experience in an Elderly Acute Lymphoblastic Leukemia Patient with Suspected Central Nervous System Involvement Transformed from Chronic Myeloid Leukemia
por: Atilla, Erden, et al.
Publicado: (2015) -
Rituximab Hypersensitivity: From Clinical Presentation to Management
por: Fouda, Ghada E., et al.
Publicado: (2020) -
Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies
por: Atilla, Pinar Ataca, et al.
Publicado: (2022) -
A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations
por: Atilla, Erden, et al.
Publicado: (2017) -
New Orders to an Old Soldier: Optimizing NK Cells for Adoptive Immunotherapy in Hematology
por: Gunduz, Mehmet, et al.
Publicado: (2021)